635 related articles for article (PubMed ID: 8610716)
21. A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease.
Matera MG; Cazzola M; Vinciguerra A; Di Perna F; Calderaro F; Caputi M; Rossi F
Pulm Pharmacol; 1995 Dec; 8(6):267-71. PubMed ID: 8819181
[TBL] [Abstract][Full Text] [Related]
22. Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease.
Ikeda A; Nishimura K; Koyama H; Izumi T
Thorax; 1995 Jan; 50(1):62-6. PubMed ID: 7886652
[TBL] [Abstract][Full Text] [Related]
23. A comparison of inhaled ipratropium, oral theophylline plus inhaled beta-agonist, and the combination of all three in patients with COPD.
Karpel JP; Kotch A; Zinny M; Pesin J; Alleyne W
Chest; 1994 Apr; 105(4):1089-94. PubMed ID: 8162730
[TBL] [Abstract][Full Text] [Related]
24. Results of a multicenter study of nebulized inhalant bronchodilator solutions.
Tashkin DP; Bleecker E; Braun S; Campbell S; DeGraff AC; Hudgel DW; Boyars MC; Sahn S
Am J Med; 1996 Jan; 100(1A):62S-69. PubMed ID: 8610720
[TBL] [Abstract][Full Text] [Related]
25. The additive effect of theophylline on a high-dose combination of inhaled salbutamol and ipratropium bromide in stable COPD.
Nishimura K; Koyama H; Ikeda A; Sugiura N; Kawakatsu K; Izumi T
Chest; 1995 Mar; 107(3):718-23. PubMed ID: 7874943
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the effects of salmeterol and ipratropium bromide on exercise performance and breathlessness in patients with stable chronic obstructive pulmonary disease.
Patakas D; Andreadis D; Mavrofridis E; Argyropoulou P
Respir Med; 1998 Sep; 92(9):1116-21. PubMed ID: 9926165
[TBL] [Abstract][Full Text] [Related]
27. Is an anticholinergic agent superior to a beta 2-agonist in improving dyspnea and exercise limitation in COPD?
Blosser SA; Maxwell SL; Reeves-Hoche MK; Localio AR; Zwillich CW
Chest; 1995 Sep; 108(3):730-5. PubMed ID: 7656624
[TBL] [Abstract][Full Text] [Related]
28. Dose response study of ipratropium bromide aerosol on maximum exercise performance in stable patients with chronic obstructive pulmonary disease.
Ikeda A; Nishimura K; Koyama H; Tsukino M; Mishima M; Izumi T
Thorax; 1996 Jan; 51(1):48-53. PubMed ID: 8658369
[TBL] [Abstract][Full Text] [Related]
29. Is oral theophylline effective in combination with both inhaled anticholinergic agent and inhaled beta 2-agonist in the treatment of stable COPD?
Nishimura K; Koyama H; Ikeda A; Izumi T
Chest; 1993 Jul; 104(1):179-84. PubMed ID: 8325065
[TBL] [Abstract][Full Text] [Related]
30. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD.
Ikeda A; Nishimura K; Izumi T
Chest; 1996 Jan; 109(1):294. PubMed ID: 8549208
[No Abstract] [Full Text] [Related]
31. Comparison of bronchodilator effects of fenoterol/ipratropium bromide and salbutamol in patients with chronic obstructive lung disease.
Imhof E; Elsasser S; Karrer W; Grossenbacher M; Emmons R; Perruchoud AP
Respiration; 1993; 60(2):84-8. PubMed ID: 8341859
[TBL] [Abstract][Full Text] [Related]
32. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD.
Dorinsky PM; Reisner C; Ferguson GT; Menjoge SS; Serby CW; Witek TJ
Chest; 1999 Apr; 115(4):966-71. PubMed ID: 10208193
[TBL] [Abstract][Full Text] [Related]
33. Bronchodilating effect of combined therapy with ipratropium bromide and ondansetron in patients with COPD.
Pauwels R; Joos GF; Fogarty C; Faiferman I; Hirschberg S; Vessey R; Wouters EF
Pulm Pharmacol Ther; 2008; 21(2):385-92. PubMed ID: 18023600
[TBL] [Abstract][Full Text] [Related]
34. Tolerance to beta 2-agonists in patients with chronic obstructive pulmonary disease.
Georgopoulos D; Wong D; Anthonisen NR
Chest; 1990 Feb; 97(2):280-4. PubMed ID: 1967572
[TBL] [Abstract][Full Text] [Related]
35. The effect of adding ipratropium bromide to salbutamol in the treatment of acute asthma: a pooled analysis of three trials.
Lanes SF; Garrett JE; Wentworth CE; Fitzgerald JM; Karpel JP
Chest; 1998 Aug; 114(2):365-72. PubMed ID: 9726716
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease.
Niewoehner DE; Lapidus R; Cote C; Sharafkhaneh A; Plautz M; Johnson P; Kesten S
Pulm Pharmacol Ther; 2009 Dec; 22(6):587-92. PubMed ID: 19737620
[TBL] [Abstract][Full Text] [Related]
37. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium.
van Noord JA; de Munck DR; Bantje TA; Hop WC; Akveld ML; Bommer AM
Eur Respir J; 2000 May; 15(5):878-85. PubMed ID: 10853852
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI.
Zuwallack R; De Salvo MC; Kaelin T; Bateman ED; Park CS; Abrahams R; Fakih F; Sachs P; Pudi K; Zhao Y; Wood CC;
Respir Med; 2010 Aug; 104(8):1179-88. PubMed ID: 20172704
[TBL] [Abstract][Full Text] [Related]
39. Bronchodilator reversibility to low and high doses of terbutaline and ipratropium bromide in patients with chronic obstructive pulmonary disease.
Newnham DM; Dhillon DP; Winter JH; Jackson CM; Clark RA; Lipworth BJ
Thorax; 1993 Nov; 48(11):1151-5. PubMed ID: 8296260
[TBL] [Abstract][Full Text] [Related]
40. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD.
Ingram RH
Chest; 1996 Jan; 109(1):293. PubMed ID: 8549206
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
